BCNU for recurrent glioblastoma multiforme: Efficacy, toxicity and prognostic factors

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Reithmeier, Thomas ^a,b   Graf, Erika ^a   Piroth, Tobias ^a   Trippel, Michael ^a   Pinsker, Marcus O ^a   Nikkhah, Guido ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; TEMOZOLOMIDE; ALKYLATING AGENT;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INFECTION; INFECTION COMPLICATION; LEUKOPENIA; LUNG DISEASE; LUNG EMBOLISM; LUNG FIBROSIS; MALE; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR VOLUME; BRAIN TUMOR; DISEASE FREE SURVIVAL; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77949882105     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-30     Document Type: Article

References (32)

1. Stupp R, Mason WP, Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996. 10.1056/NEJMoa043330, 15758009.
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999, 17:2572-2578.
3. Ammirati M, Galicich JH, Arbit E, et al. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 1987, 21:607-614.
4. Choucair AK, Levin VA, Gutin PH, et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 1986, 65:654-658. 10.3171/jns.1986.65.5.0654, 3021931.
5. Brandes AA, Fiorentino M. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 2004, 63:1281-4.
6. Zhang M, Chakravarti A. Novel radiation-enhancing agents in malignant gliomas. Semin Radiat Oncol 2006, 16:29-37. 10.1016/j.semradonc.2005.08.004, 16378904.
7. Kirches E, Scherlach C, von Bossanyi P, Schneider T, Szibor R, Kutz E, Warich-Kirches M, Dietzmann K. MGMT- and P430 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas. Clin Neuropathol 1999, 18:1-8.
8. MacDonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
9. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787. 10.1212/01.wnl.0000304121.57857.38, 18316689.
10. Sampath P, Sungarian A, Alderson L, et al. BCNU-impregnated wafers (Gliadel) plus irinotecan (Camptosar) in combination treatment for patients with recurrent glioblastoma multiforme [abstract]. Annual Meeting of the Congress of Neurological Surgeons, Boston, MA 2005,
11. Hou LC, Veeravagu A, Hsu AR, Tse VCK. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 2006, 20:E5. 10.3171/foc.2006.20.4.2, 16709036.
12. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent glioblastomas. The Polymer-brain Tumor Treatment Group. Lancet 1995, 345:1008-1012. 10.1016/S0140-6736(95)90755-6, 7723496.
13. Combs SE, Widmer V, Thilmann C. Stereotactic radiosurgery (SRS). Treatment options for recurrent glioblastoma multiforme (GBM). Cancer 2005, 104:2168-2173. 10.1002/cncr.21429, 16220556.
14. Mahajan A, McCutcheon IE, Suki D. Case-control study of stereotactic radiosurgery for recurrent glioblastoma multiforme. J Neurosurg 2005, 103:210-217. 10.3171/jns.2005.103.2.0210, 16175848.
15. Shrieve DC, Alexander E, Wen PY, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995, 36:275-284. 10.1097/00006123-199502000-00006, 7731507.
16. Chan TA, Weingart JD, Parisi M, et al. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 2005, 62:1133-1139.
17. Scharfen CO, Sneed PK, Wara WM, et al. High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 1992, 24:583-591.
18. Chamberlain MC, Kormanik PA. Practical guidelines for the treatment of malignant gliomas. West J Med 1998, 168:114-120. 1304839, 9499745.
19. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011-1018. 10.1016/S0140-6736(02)08091-1, 11937180.
20. Wick W, Steinbach JP, Küker WM, et al. One week on/one week off: a novel active regimen of temozolomide fro recurrent glioblastoma. Neurology 2004, 62:2113-2115.
21. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-9. 10.1200/JCO.2007.12.2440, 17947719.
22. Brandes AA, Tosoni A, Amistà P, Nicolardi L, Grosso RN, Berti F, Ermani M. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 2004, 63:1281-1284.
23. Brandsma D, Stalpers L, Taal W, Sminia P, Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008, 9:453-61. 10.1016/S1470-2045(08)70125-6, 18452856.
24. Liu L, Gerson SL. Targeted modulation of MGMT: Clinical implications. Clin Cancer Res 2006, 12:328-331. 10.1158/1078-0432.CCR-05-2543, 16428468.
25. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Caincross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in GBM. N Engl J Med 2005, 352:997-1003. 10.1056/NEJMoa043331, 15758010.
26. Silvani A, Gaviani P, Lamperti EA, Eoli M, Falcone C, DiMeco F, Milanesi IM, Erbetta A, Boiardi A, Fariselli L, Salmaggi A. Cisplatinum and BCNU chemotherapy in primary glioblastoma patients. J Neurooncol 2009,
27. Schold S, et al. O6-Alkylguanine-DNA alkytransferase and sensitivity to procarbazine in human braintumor xenografts. J Neurosurg 1989, 70:573-7. 10.3171/jns.1989.70.4.0573, 2926498.
28. Yarosh DB. The role of O6-methylguanine-DNA methyl-transferase in cell survival, mutagenesis, and carcinogenesis. Mutat Res 1985, 145:1-16.
29. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 1990, 87:5368-72. 10.1073/pnas.87.14.5368, 54325, 2164681.
30. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-amino-levulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006, 7:392-401. 10.1016/S1470-2045(06)70665-9, 16648043.
31. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis extent of resection, and survival. J Neurosurg 2001, 95:190-198. 10.3171/jns.2001.95.2.0190, 11780887.
32. Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol 2001, 52:161-171. 10.1023/A:1010624504311, 11508816.